GlassScriptPhysician profile
John Edward Bokosky
NPI 1245215748
$13,185.02
in general payments reported to CMS, 2019-2025
29 companies · $2,600 in 2025
The $2,600 reported for 2025 was more than what 90% of Ophthalmology providers received nationally (typical 2025 total: $384).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $945 · 2020: $1,215 · 2021: $1,483 · 2022: $2,232 · 2023: $1,450 · 2024: $3,260 · 2025: $2,600.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $7,287 · Entertainment: $23.31.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $7,287.09 |
| Entertainment | $23.31 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Alcon Vision LLC | $2,756.67 | 2019-2025 | Clareon, Argos, Clareon Panoptix Pro |
| Biotissue Holdings INC. | $2,120.39 | 2022-2025 | |
| Johnson & Johnson Surgical Vision, INC. | $951.26 | 2020-2025 | Tecnis Simplicity, Tecnis Iol |
| Bausch & Lomb, A Division of Bausch Health US, LLC | $829.89 | 2019-2021 | |
| Bausch & Lomb Americas INC. | $732.32 | 2022-2025 | Miebo, Xiidra, Crystalens Accommodating Iol (At-52ao) |
| Abbvie INC. | $605.48 | 2022-2025 | Vuity, Lumigan, Alphagan P |
| Novartis Pharmaceuticals Corporation | $595.11 | 2019-2023 | |
| Kala Pharmaceuticals, INC. | $542.29 | 2019-2022 | |
| Oyster Point Pharma, INC. | $541.03 | 2022-2025 | Tyrvaya, Ryzumvi, Ryzumvi |
| Rxsight INC | $500.43 | 2022-2024 | Rxsight Light Delivery Device (Ldd), Rxsight Injector Handpiece, Rxsight Injector Cartridge |
| Mallinckrodt Hospital Products INC. | $480.56 | 2021-2025 | Acthar |
| Sight Sciences, INC. | $467.57 | 2022-2025 | Tearcare System, Omni Surgical System |
| Harrow Eye, LLC | $384.22 | 2024-2025 | Vevye, Iheezo |
| Tarsus Pharmaceuticals, INC. | $366.94 | 2024-2025 | Xdemvy |
| Allergan, INC. | $255.61 | 2020-2022 |
Show all 29 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Amgen INC. | $247.91 | 2024-2025 | Tepezza |
| Dompe US, INC. | $150.95 | 2021-2022 | |
| Horizon Therapeutics Plc | $140.59 | 2021-2023 | Tepezza |
| Ocular Therapeutix, INC. | $97.55 | 2022-2024 | Dextenza |
| Shire North American Group INC | $97.10 | 2019 | |
| Ivantis, INC | $93.19 | 2020 | |
| Sun Pharmaceutical Industries INC. | $91.25 | 2019-2025 | |
| Eyevance Pharmaceuticals LLC | $30.51 | 2019-2021 | |
| Optos, INC. | $23.31 | 2023 | Panoramic Ophthalmoscope, Oct Ophthalmoscope, Nfc-700 |
| Carl Zeiss Meditec Ag | $19.40 | 2020 | |
| Thea Pharma INC. | $19.09 | 2023 | |
| Glaukos Corporation | $18.98 | 2024 | Photrexa |
| Iridex Corporation | $15.42 | 2019 | |
| New World Medical,INC. | $10.00 | 2022 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw John Bokosky listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.